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ABSTRACT
We report the case of a patient who had undergone injections of myoblasts in an infarct area 16
years before being referred for heart transplantation. The pathological examination of the
explanted heart found persisting myotubes embedded in ﬁbrosis. This ﬁnding supports the abil-
ity of myoblasts to survive in harsh environments, which can make them appealing candidates
for transplantation in diseases requiring supply of new myogenic cells. STEM CELLS TRANSLA-
TIONAL MEDICINE 2018;7:705–708
SIGNIFICANCE STATEMENT
The ﬁnding of engrafted myotubes in a postinfarction scar in a patient who underwent cardiac
transplantation 16 years after having received intramyocardial injections of autologous myo-
blasts supports the robustness of these cells, which could be relevant to their clinical use in
muscular dystrophies or sphincter incontinence.
In June 2000, we initiated a phase I trial of autolo-
gous myoblast transplantation in patients with
severe ischemic left ventricular dysfunction [1].
The fourth patient of this series was a 39-year-old
man who received 950 million myoblasts injected
in 31 sites in a posterior postinfarction ﬁbrous scar
measured intraoperatively at 35 cm2, in combina-
tion with a double coronary artery bypass graft. He
was then symptomatically improved over the next
9 years, with a left ventricular ejection fraction,
which increased from 22% preoperatively to a
peak value of 45% 1 year after the operation. From
2009 onward, his ejection fraction started to
decline, and 1 year later, he was admitted in a local
hospital for an acute coronary syndrome and
underwent angioplasty of a new lesion of the left
circumﬂex artery (not present in the preoperative
coronary angiogram); the saphenous vein graft
was found occluded while the internal mammary
graft was fully patent. The patient then started
to experience several episodes of heart failure
and was only transiently improved by vagal
stimulation. The worsening of this cardiac condi-
tion culminated in a cardiogenic shock in June
2016, which led to a pretransplantation check-
up. However, the repetition of episodes of heart
failure precipitated the implantation of a left
ventricular device as a bridge in December
2016, and 1 month later, he was ﬁnally
transplanted. Although the operation was ini-
tially complicated with a primary graft dysfunc-
tion, the postoperative course gradually
improved and the patient was ﬁnally discharged
in a stable condition.
The explanted heart was sent to the pathol-
ogy laboratory. Unexpectedly, several myotubes,
embedded in ﬁbrosis, were identiﬁed in 5 of
15 randomly sampled parafﬁn blocks of the
postinfarction scarred myocardial tissue. They
contained several nuclei (three to a dozen in a
given section; Fig. 1), with occasional Z striations.
Immunophenotyping of these myotubes was
positive for the following markers: myosin heavy
chain, the fast isoform (Fig. 1B, 1C) being largely
predominant over the slow one (Fig. 1); the skel-
etal isoform of troponin T (Fig. 1); the myogenic
differentiation factor myogenin (Fig. 1); and
myoglobin. Some myotubes also expressed CD56
(N-CAM, a marker of satellite cells, myoblasts,
and myotubes; Fig. 1). Altogether, these features
reﬂected the skeletal muscle origin of the cells
that were identiﬁed in the scar. However,
markers of quiescent myogenic cells (Pax7) or of
early-committed myoblasts (MyoD1) were not
observed. The transplanted cells presented no
replicating activity as they were negative for the
expression of the proliferating cell nuclear anti-
gen. The cardiac markers GATA4 and connexin
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43 were not expressed either in the grafted area, although they
were identiﬁed in the neighboring cardiac tissue. The intermedi-
ate ﬁlament desmin, which is normally present in both skeletal,
smooth, and cardiac muscle cells, was accordingly expressed by
single cells and myotubes in the injected area, vessel cells, and
the neighboring cardiomyocytes. Nerve cells positive for PS100
and neuroﬁlament antibodies were present in the injected area
but did not project over the myogenic structures.
The identiﬁcation of some cells engrafted 16 years earlier
in a postinfarction scar is at variance with most of the pub-
lished studies, which have reported that intramyocardially
transplanted cells are usually short-lived [2, 3]. This excep-
tional longevity is likely due to the speciﬁc capacity of myo-
blasts to resist injurious stresses and was yet demonstrated by
their presence in a skeletal muscle 18 months following trans-
plantation in a patient with Duchenne muscular dystrophy [4].
Likewise, in the heart, previous experimental data have shown
persistence of intramyocardially delivered myoblasts at
3 months in rats [5] and until 1 year in a sheep model of myo-
cardial infarction [6]. Human data conﬁrm these ﬁndings
regardless of whether they were obtained from biopsy speci-
mens taken either at the time of heart transplantation in
patients previously implanted with an assist device combined
with myoblast transplantation [7, 8] or during an autopsy [9].
So far, however, the longest clinical follow-up was limited to
17.5 months [9]. The 16-year follow-up reported in the current
observation is thus probably the longest one ever documented
after any type of cell transplantation in the heart.
Histologically, the engrafted cells displayed typical patterns
of myotubes and expressed the fast (glycolytic) isoform of myo-
sin heavy chain even though they may have incurred milieu-
induced phenotypic changes accounting for some expression of
the slow-type myosin heavy chain isoform, characterized by an
oxidative metabolism. This ﬁnding suggests that some cells could
rely on both glycolytic and oxidative metabolic pathways, which
might have endowed them with a survival advantage in this
environment. Mechanistically, the persisting engraftment of
myoblasts in a cardiac milieu intrinsically different from their
speciﬁc one suggests that transplanted myoblasts and graft-
derived myotubes may survive for years without the support of
a classically organized myogenic niche, although the negativity
of Pax-7 staining suggests that the grafted myoblasts did not
regenerate quiescent satellite cells, possibly because of the lack
of supportive basal laminae under which they normally reside.
The engrafted myotubes were found insulated from the neigh-
boring cardiomyocytes and did not express connexin 43, which
conﬁrms the lack of an electrical integration at the graft-host
interface [10]. This pattern has been held responsible for the
arrhythmias reported after myoblast transplantation in the heart.
Indeed, our patient presented an early postoperative arrhythmic
storm, which led to the implantation of an internal cardioverter-
deﬁbrillator. No further noticeable arrhythmic episodes were
Figure 1. Histological and immunochemical ﬁndings in the native
heart at the site of the cell-transplanted myocardial infarction.
(A): Multinucleated skeletal muscle cells/myotubes (arrows)
embedded in ﬁbrosis. Inset shows the Z-bands in a skeletal muscle
cell. Hematoxylin & Eosin staining. Original ×40 and ×100 for
inset. (B): Large sub-epicardial focus (black outline) of grafted skel-
etal muscle cells expressing the fast isoform of the skeletal muscle
myosin heavy chain. Original ×2.5. (C): Strong expression of the
fast isoform of the skeletal muscle myosin heavy chain (MYH1) by
several cells. Although the density of skeletal muscle cells is high,
they are separated by ﬁbrosis. Original ×20. (D): Expression of the
slow isoform of the skeletal muscle myosin heavy chain (MYH7)
by a small proportion of the grafted cells. Original ×20. (E):
Expression of the skeletal troponin T (TNNT3) fast isoform by the
grafted skeletal muscle cells. Original ×40. (F): Expression of the
myogenin transcription factor in nuclei of the grafted skeletal
muscle cells (arrow). Original ×40. (G): Expression of CD56 by
myotubes. Original ×40.
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observed during the follow-up despite the persisting engraft-
ment of some of the cells. It is possible that aside from the cel-
lular phenotype, the mode of cell delivery, which was based on
multiple intramyocardial injections, has played a role in the gen-
esis of these early postprocedural arrhythmias. as a recent clini-
cal study reported the absence of electrical instability when
myoblasts were delivered under the form of epicardial sheets
[11]. Mechanistically, the ﬁnding that myoﬁber bundles were
embedded in scar tissue makes it unlikely that they contributed
to improve heart contractility. However, if one assumes that, in
combination with the coronary artery bypass, myoblast grafting
may have helped in stabilizing the patient’s cardiac condition for
9 years, it is conceivable that the underlying mechanism of
action was paracrine, because myoblasts have been shown
to release factors involved in several pathways including
preservation of matrix architecture [12], decrease in ﬁbrosis
[13] and apoptosis [14], stimulation of angiogenesis [14], and
mitigation of oxidative stress [15]. Of note, in the last com-
puted tomography scan, which was performed 6 months
before heart transplantation, the seven inferior wall seg-
ments corresponding in part to the infarcted myoblast-
transplanted area were assessed as hypokinetic (i.e., not
completely akinetic, in contrast to other areas of the heart).
Although these data must be interpreted very cautiously,
they may suggest that the paracrine effects of the trans-
planted cells possibly contributed to slightly improve the con-
tractility of the target area, more likely by acting on the still
viable peri-infarct tissue rather than by actually reducing the
size of the core infarct. We acknowledge, however, that in
the absence of serial measurements of infarct size through-
out the 16-year follow-up, no deﬁnite conclusions can be
drawn regarding the precise mechanism of action of the
transplanted cells.
Although this observation is unlikely to rekindle interest
in grafting myoblasts in patients with severe heart failure, it
supports the robustness of these cells, reﬂected by their sur-
vival in a hostile, poorly vascularized environment and in the
absence of any observed innervation. As such, the current
ﬁndings could be relevant to current or future applications
of skeletal muscle cell-derived therapy in muscular dystro-
phies [16–18] or urinary [19, 20] or anal sphincter inconti-
nence [21].
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